PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 2,484 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 2,484 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $172,290.24. Following the completion of the transaction, the executive vice president owned 89,944 shares of the company’s stock, valued at $6,238,515.84. This represents a 2.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lee Scott Golden also recently made the following trade(s):

• On Thursday, January 8th, Lee Scott Golden sold 866 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total transaction of $66,205.70.
• On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $49,742.16.
• On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $103,113.00.

PTC Therapeutics Stock Up 1.1%

NASDAQ PTCT traded up $0.76 during mid-day trading on Friday, hitting $70.66. The stock had a trading volume of 2,532,077 shares, compared to its average volume of 1,290,685. The company has a 50 day simple moving average of $75.01 and a 200 day simple moving average of $67.78. The company has a market cap of $5.67 billion, a price-to-earnings ratio of 8.25 and a beta of 0.48. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm had revenue of $164.68 million for the quarter, compared to analysts’ expectations of $281.45 million. During the same quarter in the previous year, the firm posted ($0.85) earnings per share. The firm’s revenue for the quarter was down 22.7% compared to the same quarter last year. As a group, equities analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PTC Therapeutics

Several hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its position in PTC Therapeutics by 3.0% during the second quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company’s stock worth $388,000 after purchasing an additional 231 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 236 shares during the period. Allworth Financial LP grew its stake in shares of PTC Therapeutics by 63.8% during the 4th quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 247 shares during the period. Optiver Holding B.V. increased its holdings in shares of PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 249 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC raised its position in shares of PTC Therapeutics by 5.6% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 4,963 shares of the biopharmaceutical company’s stock worth $377,000 after buying an additional 265 shares during the period.

Analysts Set New Price Targets

Several analysts have recently commented on PTCT shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of PTC Therapeutics in a research report on Friday. Wells Fargo & Company lowered their target price on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a report on Friday. TD Cowen reissued a “hold” rating on shares of PTC Therapeutics in a report on Thursday, January 29th. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Jefferies Financial Group lifted their price objective on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Ten analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.73.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.